| | |  | | | | Record from Web of Science® | | | | | | |
| Decreased susceptibility to renovascular hypertension in mice lacking the prostaglandin I-2 receptor IP |
|
|
| Author(s): Fujino T, Nakagawa N, Yuhki K, Hara A, Yamada T, Takayama K, Kuriyama S, Hosoki Y, Takahata O, Taniguchi T, Fukuzawa J, Hasebe N, Kikuchi K, Narumiya S, Ushikubi F |
| Source: JOURNAL OF CLINICAL INVESTIGATION Volume: 114 Issue: 6 Pages: 805-812 Published: SEP 2004 |
| Times Cited: 27 References: 33 |
| Abstract: Persistent reduction of renal perfusion pressure induces renovascular hypertension by activating the reninangiotensin-aldosterone system; however, the sensing mechanism remains elusive. Here we investigated the role of PGI(2) in renovascular hypertension in vivo, employing mice lacking the PGI(2) receptor (IP-/- mice). In WT mice with a two-kidney, one-clip model of renovascular hypertension, the BP was significantly elevated. The increase in BP in IP-/- mice, however, was significantly lower than that in WT mice. Similarly, the increases in plasma renin activity, renal renin mRNA, and plasma aldosterone in response to renal artery stenosis were all significantly lower in IP-/- mice than in WT mice. All these parameters were measured in mice lacking the four PGE(2) receptor subtypes individually, and we found that these mice had similar responses to WT mice. PGI(2) is produced by COX-2 and a selective inhibitor of this enzyme, SC-58125, also significantly reduced the increases in plasma renin activity and renin mRNA expression in WT mice with renal artery stenosis, but these effects were absent in IP-/- mice. When the renin-angiotensin-aldosterone system was activated by salt depletion, SC-58125 blunted the response in WT mice but not in IP-/- mice. These results indicate that PGI(2) derived from COX-2 plays a critical role in regulating the release of renin and consequently renovascular hypertension in vivo. |
| Document Type: Article |
| Language: English |
| Reprint Address: Ushikubi, F (reprint author), Asahikawa Med Coll, Dept Pharmacol, Midorigaoka Higashi 2-1-1-1, Asahikawa, Hokkaido 0788510 Japan |
Addresses:
1. Asahikawa Med Coll, Dept Pharmacol, Asahikawa, Hokkaido 0788510 Japan
2. Asahikawa Med Coll, Dept Biochem, Asahikawa, Hokkaido 078 Japan
3. Asahikawa Med Coll, Dept Internal Med 1, Asahikawa, Hokkaido Japan
4. Kyoto Univ, Fac Med, Dept Pharmacol, Kyoto 606, Japan |
| Publisher: AMER SOC CLINICAL INVESTIGATION INC, 35 RESEARCH DR, STE 300, ANN ARBOR, MI 48103 USA |
| Subject Category: Medicine, Research & Experimental |
| IDS Number: 853ZE |
| ISSN: 0021-9738 |
| DOI: 10.1172/JCI200421382 |
|
| | | | | | | | | Record from Web of Science® | | | | | | | | | |